Endpoints Weekly celebrates Neal Awards while previewing Sanofi, Lilly and RevMed updates
Endpoints Weekly released its latest edition on April 25, 2026, noting a celebratory tone after the publication earned three Neal Awards for B2B journalism excellence.
The issue highlights several industry developments, including Sanofi’s ongoing challenges in immunology, Lilly’s acquisition of an in vivo CAR-T biotech company, and RevMed’s progress that the outlet likens to a “Herceptin moment.”
While the article does not provide detailed data on these stories, it signals that these topics will be explored further in upcoming coverage.
Readers are invited to sign up for free access to a limited number of articles and can subscribe for full newsletter delivery.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Sanofi’s immunology reckoning; Lilly acquires in vivo CAR-T biotech; RevMed’s ‘Herceptin moment’; and more”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that